MedTrace Logo

Quality of Life as a Predictor of OS and PFS in Patients With Lung Cancer

NCT06900283 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 320

Last updated 2025-04-03

No results posted yet for this study

Summary

By 2020, lung cancer continues leading the first cause of cancer mortality and the second most common type of cancer in the world. There are limitations to early detection and then more than 60% of patients are diagnosed in advanced stages where there are no longer curative options; that situation is associated with high mortality and poor survival. It is known that some clinical and biochemical parameters of the disease have been recognized as prognostic factors; however, it has been described that a reduction in the overall global quality of life score, mainly by physical function, increased pain, and dysphagia, are associated with mortality, and having high social well-being and global quality of life scores are associated with a lower risk of death.

Objective: This study will measure association between Health-Related Quality of Life levels and mortality and progression free survival in advanced non-small cell lung cancer patients

Patients and methods:

This study will include patients with lung cancer histopathological confirmed including bronchus or trachea.

Methodologically, the study has two components: One related to the exposure variable (HRQL), which involves a scale validation study, and other related to the measurement of the association between HRQoL and survival outcomes, which involves a prospective cohort analytical observational study. This last component will be carried out specifically with a sample of patients with non-small cell lung cancer (NSCLC).

Results and impact: The project contribute to the implementation of tools adapted and validated in the Colombian context to assess the quality of life in patients with lung cancer. Additionally, knowing the relationship between quality of life and traditional oncological outcomes will provide tools to give patients with comprehensive treatment, and to have a prognosis of the disease that incorporates psychosocial aspects

Conditions

Sponsors & Collaborators

  • Hospital Universitario San Ignacio

    collaborator OTHER

  • Hospital Pablo Tobón Uribe

    collaborator OTHER

  • Hospital Alma Mater de Antioquia

    collaborator UNKNOWN

  • Instituto Nacional de Cancerologia, Columbia

    lead OTHER_GOV

Principal Investigators

  • Jose A Carreno, Md · Instituto Nacional de Cancerologia, Columbia

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-01
Primary Completion
2025-12-01
Completion
2025-12-31

Countries

  • Colombia

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06900283 on ClinicalTrials.gov